AlphAIalphai — Financial news for AI agents
GuruFocusAPR 113 min read$OMCL

Omnicell Inc (OMCL) Shares Fall 3.0% -- What GF Score of 79 Tells Investors

Omnicell Inc (OMCL) shares fell 3.0% to $34.40. The company is considered undervalued by 9.3% based on its GF Value™ of $37.91, yet its GF Score™ of 79/100 suggests above-average quality. Despite the undervaluation, its current P/E ratio of 860.0x is significantly higher than its 5-year median, and insiders have sold $0.4 million worth of shares recently, with no reported buying, indicating a cautious outlook.

Original reporting
GuruFocus · GuruFocus News
Published Apr 11, 2026, 10:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 11, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Omnicell Inc (OMCL) Shares Fall 3.0% -- What GF Score of 79 Tells Investors — source image
Source · GuruFocus
Decision brief

The 30-second read

$OMCLNeutralMed
01

Why it matters

Recent share decline may be due to valuation concerns rather than fundamental business deterioration.

02

Market read

The news is moderately relevant for investors in healthcare technology, especially those focusing on valuation and insider activity.

03

What to watch

Potential upcoming catalysts such as product launches or strategic partnerships that could improve outlook.

Timing: short to medium term (next 1-3 months)

Background

Omnicell Inc operates in healthcare technology, providing automation solutions for medication management.

Company-level read

Ticker impact

$OMCLNeutralMedium confidence
Context

The news highlights a recent decline in Omnicell Inc (OMCL) shares and provides valuation and insider trading insights.

Expected impact

Potential short-term stabilization or slight rebound if undervaluation attracts value investors; long-term outlook remains cautious due to high P/E and insider activity.

Evidence & confidence

The valuation metrics and insider sales indicate mixed signals; technical indicators and broader market conditions are not provided, limiting prediction accuracy.

Market effects

Sector

The decline and valuation concerns may reflect broader challenges in the healthcare technology sector.

Regional

Limited regional impact; company-specific factors dominate.

Global

Moderate; reflects investor caution towards healthcare tech valuations.

Counterpoint

What could challenge this read

The undervaluation suggests a potential buying opportunity for long-term investors willing to accept short-term volatility.

Key entities

  • Company
    Omnicell Inc

    A provider of medication management solutions.

  • Group
    Insiders

    Executives and major shareholders selling shares recently.

Read at source← All news

Related articles

JUL 30
$OMCLMedAI 8/10

Omnicell (OMCL) Stock Trades Down, Here Is Why

Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.

financialcontent.com4 min
JUL 30
$OMCLHigh

OMNICELL, INC. (OMCL): Results of Operations and Financial Condition

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2-26.htm EX-99.1 Document Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quart

SEC EDGAR 8-K6 min
AUG 9
$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

dailysabah.com6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min